CytRx Total Assets 2006-2021 | CYTR

CytRx total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
CytRx Annual Total Assets
(Millions of US $)
2020 $12
2019 $17
2018 $23
2017 $48
2016 $63
2015 $67
2014 $86
2013 $42
2012 $40
2011 $38
2010 $37
2009 $35
2008 $28
2007 $64
2006 $32
2005 $10
CytRx Quarterly Total Assets
(Millions of US $)
2021-09-30 $17
2021-06-30 $9
2021-03-31 $11
2020-12-31 $12
2020-09-30 $15
2020-06-30 $16
2020-03-31 $17
2019-12-31 $17
2019-09-30 $20
2019-06-30 $20
2019-03-31 $22
2018-12-31 $23
2018-09-30 $33
2018-06-30 $44
2018-03-31 $43
2017-12-31 $48
2017-09-30 $50
2017-06-30 $58
2017-03-31 $53
2016-12-31 $63
2016-09-30 $64
2016-06-30 $60
2016-03-31 $75
2015-12-31 $67
2015-09-30 $77
2015-06-30 $63
2015-03-31 $74
2014-12-31 $86
2014-09-30 $97
2014-06-30 $106
2014-03-31 $115
2013-12-31 $42
2013-09-30 $24
2013-06-30 $29
2013-03-31 $35
2012-12-31 $40
2012-09-30 $24
2012-06-30 $29
2012-03-31 $33
2011-12-31 $38
2011-09-30 $45
2011-06-30 $29
2011-03-31 $33
2010-12-31 $37
2010-09-30 $42
2010-06-30 $44
2010-03-31 $36
2009-12-31 $35
2009-09-30 $37
2009-06-30 $21
2009-03-31 $25
2008-12-31 $28
2008-09-30 $36
2008-06-30 $43
2008-03-31 $51
2007-12-31 $64
2007-09-30 $68
2007-06-30 $73
2007-03-31 $38
2006-12-31 $32
2006-09-30 $35
2006-06-30 $14
2006-03-31 $19
2005-12-31 $10
2005-09-30 $13
2005-06-30 $17
2005-03-31 $21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.022B $0.000B
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75